Is it a buy? Leading brokers analyse the Westpac (ASX:WBC) share price

Let's see what the experts are saying about the bank's prospects.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in the banking big 4 member Westpac Banking Corporation (ASX: WBC) are inching higher this morning and now trade less than 1% in the green at $20.90.

Westpac shares started to tumble at the end of October after the company revealed its full-year results, leaving many investors and analysts alike unimpressed with its performance.

The Westpac share price has come down hard from a high of $26.23 in October and continued its downward path until climbing again in December.

With this in mind, several leading investment firms have afforded us their opinion on the outlook for Westpac investors. So is Westpac a buy? Let's find out.

a panel of formidible business people stand in a group with serious looks on their faces as if in judgement of what's before them.

Image source: Getty Images

What are brokers saying about Westpac?

The team at Citi reckons Westpac is a buy right now. However, in a recent note, the firm also acknowledges Westpac's off-market buyback is of less value compared to that of banking rival CBA.

It notes that the complex moving parts involved with off-market buybacks have created a peculiar situation for the bank. This comes after it recently extended the tender period and reworked the discount it was awarding on the offer.

Even after the revision, the bank's post-tax returns are still a way behind CBA's 13% gain, the broker notes. City says, "With less tax benefits on offer, we expect Westpac will likely receive significantly less demand than CBA but has pledged to redirect any shortfall into an on-market buy-back."

Nevertheless, Citi has Westpac as a buy and is attracted to the bank's current valuation after the pullback in its share price over the last 2 months.

Fellow investment bank Jefferies isn't so rosy on the outlook for Westpac shares, noting it needs a cultural overhaul rather than focusing on its $8 billion cost-reset strategy in FY24.

Jefferies also is critical of Westpac's buyback, noting the $3.5 billion off-market purchase of its own shares is less attractive due to the run down in its share price. It says this effectively reduces the fully-franked dividend component of the buyback.

It also forecasts another compression of Westpac's net interest margin (NIM) in its trading update in January. It points out potential investor dissatisfaction on the horizon if shareholders employ the first no vote strike on its remuneration report at its AGM tomorrow.

Jefferies has Westpac as a hold and values the company at $19.20, implying a small percentage of downside potential at the time of writing.

Finally, Goldman Sachs also weighed in on Westpac's investment debate in a recent note. Goldman says the bank's recent results are an indication of a weak platform to grow revenue in FY22.

It too retains its neutral rating on the banking major and thinks the market might need to apply a heavier discount on Westpac's potential to reach its FY24 $8 billion cost target.

Goldman values the bank at $25.60 per share, even with its neutral rating, implying almost $5 of upside potential at the time of writing.

Meanwhile, Morgans has Westpac as a buy, whereas Jarden, Barrenjoey, and Evans & Partners have it as a sell.

Westpac share price summary

In the last 12 months, the Westpac share price has gained just over 4%, climbing 8% this year to date.

However, during the past single-month period to date, it has reversed course and is now trading around 8% in the red.

The author has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Westpac Banking Corporation. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Down 43% this week, are Cochlear shares now the best bargain buy of the year?

A leading analyst believes the historic selloff in Cochlear shares could present a unique buying opportunity.

Read more »

A smiling woman at a hardware shop selects paint colours from a wall display.
Broker Notes

Wesfarmers shares: Buy, hold or sell?

A leading analyst delivers his verdict on Wesfarmers shares.

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Broker Notes

Buy, hold, sell: Cochlear, CSL, and DroneShield shares

Are these hugely popular shares in the buy zone or not? Let's find out.

Read more »

Man with rocket wings which have flames coming out of them.
Broker Notes

These ASX 200 shares could rise ~40% to 80%

Brokers are predicting big returns for these top shares. Here's what you need to know.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Broker Notes

2 ASX 200 stocks that could rise 50%

Morgans thinks the market is undervaluing these shares.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy right now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Dollar sign in yellow with a red falling arrow in front of a graph, symbolising a falling share price.
Broker Notes

6 ASX 200 shares downgraded by brokers this week

Brokers have reduced their ratings on TechnologyOne, Macquarie, 4DMedical, and others this week.

Read more »